MGI Pharma MOGN New patents, anti cancer Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (1130)	11/17/1998 6:50:00 PM
From: David Cathcart	Read Replies (1) of 1826

Peter, >>Upbeat (a little too so for my taste) news release<< I defer to your knowledge and experience on this judgement. I like the fact though that the one pancreatic patient is still in the phase I trial after six months and has had a >70% tumor reduction. I realize that one patient is simply an “observation,” but this one is a really nice observation. The drug does not have to work nearly that well in the phase II trial for MGI 114 to be the better mousetrap for pancreatic cancer. “Oh maybe not today, and maybe not tomorrow, but soon…” the street is going to start liking MGI 114 and the company that owns it. Maybe it will be tomorrow. David

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next